Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
February 4, 2025
Enveric Biosciences Announces Closing of $5 Million Public Offering
February 3, 2025
Enveric Biosciences Announces Pricing of $5 Million Public Offering
January 30, 2025
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
January 30, 2025
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
January 6, 2025
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
January 6, 2025
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
December 2, 2024
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
November 25, 2024
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
November 14, 2024
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
November 12, 2024
1
2
3
…
14
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin